Leptomeningeal Metastasis

 

 Buy Article Permissions and Reprints

ABSTRACT

Leptomeningeal metastasis occurs in ~5% of all patients with cancer and is the third most common metastatic complication of the central nervous system. Staging of leptomeningeal metastasis includes contrast-enhanced brain and spine magnetic resonance imaging and radionuclide cerebrospinal fluid (CSF) flow study. Treatment, when clinically indicated, often requires administration of involved-field radiotherapy to bulky or symptomatic disease sites as well as intra-CSF and systemic chemotherapy. The use of high-dose systemic therapy may benefit selected patients with breast- or lymphoma-related leptomeningeal metastasis and obviate the need for intra-CSF chemotherapy. Intra-CSF drug therapy primarily utilizes one of three chemotherapeutic agents (e.g., methotrexate, cytosine arabinoside, and thiotepa) administered by a variety of schedules either by intralumbar or intraventricular drug delivery. Beginning to be utilized are novel intra-CSF agents, such as the targeted monoclonal antibodies rituximab (anti-CD20 for B-cell lymphoma-related leptomeningeal metastasis) and trastuzumab (anti-Her2/neu for breast cancer-related leptomeningeal metastasis). Although treatment of leptomeningeal metastasis is palliative with median patient survival of 2 to 3 months, treatment may afford stabilization and protection from further neurologic deterioration in patients with leptomeningeal metastasis.

REFERENCES

• 1 Jaeckle K A. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment.  Semin Oncol. 2006;  33(3) 312-323
  CrossrefPubMedGoogle Scholar
• 2 Pace A, Fabi A. Chemotherapy in neoplastic meningitis.  Crit Rev Oncol Hematol. 2006;  60(3) 194-200
  CrossrefPubMedGoogle Scholar
• 3 Kaplan J G, DeSouza T G, Farkash A et al.. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias.  J Neurooncol. 1990;  9(3) 225-229
  CrossrefPubMedGoogle Scholar
• 4 Siegal T, Lossos A, Pfeffer M R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy.  Neurology. 1994;  44(8) 1463-1469
  PubMedGoogle Scholar
• 5 Blaney S M, Poplack D G. Neoplastic meningitis: diagnosis and treatment considerations.  Med Oncol. 2000;  17(3) 151-162
  CrossrefPubMedGoogle Scholar
• 6 Glass J P, Melamed M, Chernik N L, Posner J B. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology.  Neurology. 1979;  29(10) 1369-1375
  PubMedGoogle Scholar
• 7 Wasserstrom W R, Glass J P, Posner J B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.  Cancer. 1982;  49(4) 759-772
  CrossrefPubMedGoogle Scholar
• 8 Rosen S T, Aisner J, Makuch R W et al.. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience.  Medicine (Baltimore). 1982;  61(1) 45-53
  CrossrefPubMedGoogle Scholar
• 9 Amer M H, Al-Sarraf M, Baker L H, Vaitkevicius V K. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.  Cancer. 1978;  42(2) 660-668
  CrossrefPubMedGoogle Scholar
• 10 van Oostenbrugge R J, Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases.  Neurology. 1999;  53(2) 382-385
  CrossrefPubMedGoogle Scholar
• 11 Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors.  Arch Neurol. 1996;  53(7) 626-632
  CrossrefPubMedGoogle Scholar
• 12 Sorensen S C, Eagan R T, Scott M. Meningeal carcinomatosis in patients with primary breast or lung cancer.  Mayo Clin Proc. 1984;  59(2) 91-94
  PubMedGoogle Scholar
• 13 Gonzalez-Vitale J C, Garcia-Bunuel R. Meningeal carcinomatosis.  Cancer. 1976;  37(6) 2906-2911
  CrossrefPubMedGoogle Scholar
• 14 Gleissner B, Chamberlain M C. Neoplastic meningitis.  Lancet Neurol. 2006;  5(5) 443-452
  CrossrefPubMedGoogle Scholar
• 15 Boyle R, Thomas M, Adams J H. Diffuse involvement of the leptomeninges by tumour—a clinical and pathological study of 63 cases.  Postgrad Med J. 1980;  56(653) 149-158
  CrossrefPubMedGoogle Scholar
• 16 Wolfgang G, Marcus D, Ulrike S. Leptomeningeal carcinomatosis; clinical syndrome in different primaries.  J Neurooncol. 1998;  38 103-110
  CrossrefPubMedGoogle Scholar
• 17 Kölmel H W. Cytology of neoplastic meningosis.  J Neurooncol. 1998;  38(2-3) 121-125
  CrossrefPubMedGoogle Scholar
• 18 Murray J J, Greco F A, Wolff S N, Hainsworth J D. Neoplastic meningitis. Marked variations of cerebrospinal fluid composition in the absence of extradural block.  Am J Med. 1983;  75(2) 289-294
  CrossrefPubMedGoogle Scholar
• 19 Rogers L R, Duchesneau P M, Nunez C et al.. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis.  Neurology. 1992;  42(6) 1239-1241
  PubMedGoogle Scholar
• 20 Chamberlain M C, Kormanik P A, Glantz M J. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases.  Neuro-oncol. 2001;  3(1) 42-45
  PubMedGoogle Scholar
• 21 Glantz M J, Cole B F, Glantz L K et al.. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results.  Cancer. 1998;  82(4) 733-739
  CrossrefPubMedGoogle Scholar
• 22 Groves M D, Hess K R, Puduvalli V K et al.. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.  J Neurooncol. 2009;  94(2) 229-234
  CrossrefPubMedGoogle Scholar
• 23 Chamberlain M C. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers.  Neurology. 1998;  50(4) 1173-1175
  PubMedGoogle Scholar
• 24 Hovestadt A, Henzen-Logmans S C, Vecht C J. Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis.  Br J Cancer. 1990;  62(4) 653-654
  CrossrefPubMedGoogle Scholar
• 25 van Oostenbrugge R J, Hopman A H, Ramaekers F C, Twijnstra A. In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis.  J Neurooncol. 1998;  38(2-3) 127-133
  CrossrefPubMedGoogle Scholar
• 26 Quijano S, López A, Manuel Sancho J Spanish Group for the Study of CNS Disease in NHL et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.  J Clin Oncol. 2009;  27(9) 1462-1469
  CrossrefPubMedGoogle Scholar
• 27 Bromberg J EC, Breems D A, Kraan J et al.. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies.  Neurology. 2007;  68(20) 1674-1679
  CrossrefPubMedGoogle Scholar
• 28 Hegde U, Filie A, Little R F et al.. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.  Blood. 2005;  105(2) 496-502
  CrossrefPubMedGoogle Scholar
• 29 Cheng T M, O'Neill B P, Scheithauer B W, Piepgras D G. Chronic meningitis: the role of meningeal or cortical biopsy.  Neurosurgery. 1994;  34(4) 590-595 discussion 596
  CrossrefPubMedGoogle Scholar
• 30 Chamberlain M C, Sandy A D, Press G A. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain.  Neurology. 1990;  40(3 Pt 1) 435-438
  PubMedGoogle Scholar
• 31 Schumacher M, Orszagh M. Imaging techniques in neoplastic meningiosis.  J Neurooncol. 1998;  38(2-3) 111-120
  CrossrefPubMedGoogle Scholar
• 32 Chamberlain M C. Comparative spine imaging in leptomeningeal metastases.  J Neurooncol. 1995;  23(3) 233-238
  CrossrefPubMedGoogle Scholar
• 33 Freilich R J, Krol G, DeAngelis L M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis.  Ann Neurol. 1995;  38(1) 51-57
  CrossrefPubMedGoogle Scholar
• 34 Mittl Jr R L, Yousem D M. Frequency of unexplained meningeal enhancement in the brain after lumbar puncture.  AJNR Am J Neuroradiol. 1994;  15(4) 633-638
  PubMedGoogle Scholar
• 35 Chamberlain M C. Radioisotope CSF flow studies in leptomeningeal metastases.  J Neurooncol. 1998;  38(2-3) 135-140
  CrossrefPubMedGoogle Scholar
• 36 Glantz M J, Hall W A, Cole B F et al.. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status.  Cancer. 1995;  75(12) 2919-2931
  CrossrefPubMedGoogle Scholar
• 37 Grossman S A, Trump C L, Chen D C, Thompson G, Camargo E E. Cerebrospinal flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography.  Am J Med. 1982;  73 641-647
  CrossrefPubMedGoogle Scholar
• 38 Chamberlain M C, Kormanik P A. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases.  Neurology. 1996;  46(6) 1674-1677
  PubMedGoogle Scholar
• 39 Mason W P, Yeh S D, DeAngelis L M. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases.  Neurology. 1998;  50(2) 438-444
  PubMedGoogle Scholar
• 40 Chamberlain M C, Corey-Bloom J. Leptomeningeal metastases: 111indium-DTPA CSF flow studies.  Neurology. 1991;  41(11) 1765-1769
  PubMedGoogle Scholar
• 41 Chamberlain M C, Kormanik P, Jaeckle K A, Glantz M. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases.  Neurology. 1999;  52(1) 216-217
  PubMedGoogle Scholar
• 42 Chamberlain M C, Kormanik P A. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases.  Arch Neurol. 1997;  54(11) 1364-1368
  PubMedGoogle Scholar
• 43 Chamberlain M C. Neoplastic meningitis-related encephalopathy: prognostic significance.  Neurology. 2004;  63 2159-2161
  PubMedGoogle Scholar
• 44 Chamberlain M C. Neoplastic meningitis: deciding who to treat.  Expert Rev Neurother. 2004;  4 89-96
  PubMedGoogle Scholar
• 45 Brem S S, Bierman P J, Black P et al.. Central nervous system cancers.  J Natl Compr Canc Netw. 2008;  6(5) 456-504
  PubMedGoogle Scholar
• 46 Shapiro W R, Young D F, Mehta B M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.  N Engl J Med. 1975;  293(4) 161-166
  CrossrefPubMedGoogle Scholar
• 47 Grossman S A, Finkelstein D M, Ruckdeschel J C, Trump D L, Moynihan T, Ettinger D S. Eastern Cooperative Oncology Group . Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis.  J Clin Oncol. 1993;  11(3) 561-569
  PubMedGoogle Scholar
• 48 Glantz M J, Jaeckle K A, Chamberlain M C et al.. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.  Clin Cancer Res. 1999;  5(11) 3394-3402
  PubMedGoogle Scholar
• 49 Glantz M J, LaFollette S, Jaeckle K A et al.. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.  J Clin Oncol. 1999;  17(10) 3110-3116
  PubMedGoogle Scholar
• 50 Shapiro W R, Schmid M, Glantz M, Miller J J. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis.  J Clin Oncol. 2006;  24(Suppl) 1528 (Abstract)
  PubMedGoogle Scholar
• 51 Chamberlain M C. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis.  Cancer. 2002;  94(10) 2675-2680
  CrossrefPubMedGoogle Scholar
• 52 Chamberlain M C, Wei-Tsao D D, Groshen S. Phase 2 trial of intra-CSF etoposide in the treatment of neoplastic meningitis.  Cancer. 2006;  106(9) 2021-2027
  CrossrefPubMedGoogle Scholar
• 53 Groves M D, Glantz M J, Chamberlain M C et al.. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.  Neuro-oncol. 2008;  10(2) 208-215
  PubMedGoogle Scholar
• 54 Chamberlain M C, Johnston S K, Van Horn A, Glantz M J. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C.  J Neurooncol. 2009;  91(3) 271-277
  CrossrefPubMedGoogle Scholar
• 55 Rubenstein J L, Fridlyand J, Abrey L et al.. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.  J Clin Oncol. 2007;  25(11) 1350-1356
  CrossrefPubMedGoogle Scholar
• 56 Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.  Ann Oncol. 2008;  19(11) 1978-1980
  CrossrefPubMedGoogle Scholar
• 57 Allison D, Glantz M. Intra-CSF Trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors.  Neurology. 2009;  72(11, Suppl 3) A30
  PubMedGoogle Scholar
• 58 Chamberlain M C. Risk of neoplastic meningitis following surgical resection of cerebellar metastases.  J Neurooncol. 2008;  89(1) 105-107
  CrossrefPubMedGoogle Scholar
• 59 Berweiler U, Krone A, Tonn J C. Reservoir systems for intraventricular chemotherapy.  J Neurooncol. 1998;  38(2-3) 141-143
  CrossrefPubMedGoogle Scholar
• 60 Sandberg D I, Bilsky M H, Souweidane M M, Bzdil J, Gutin P H. Ommaya reservoirs for the treatment of leptomeningeal metastases.  Neurosurgery. 2000;  47(1) 49-54 discussion 54-55
  CrossrefPubMedGoogle Scholar
• 61 Glantz M J, Van Horn A, Fisher R, Chamberlain M C. Route of intra-CSF chemotherapy administration and efficacy of therapy in neoplastic meningitis.  Cancer. 2010;  116(8) 1947-1952
  CrossrefPubMedGoogle Scholar
• 62 Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?.  J Neurooncol. 1998;  38(2-3) 151-157
  CrossrefPubMedGoogle Scholar
• 63 Boogerd W, van den Bent M J, Koehler P J et al.. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study.  Eur J Cancer. 2004;  40(18) 2726-2733
  CrossrefPubMedGoogle Scholar
• 64 Hitchins R N, Bell D R, Woods R L, Levi J A. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis.  J Clin Oncol. 1987;  5(10) 1655-1662
  PubMedGoogle Scholar
• 65 Chamberlain M C, Kormanik P A, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases.  J Neurosurg. 1997;  87(5) 694-699
  CrossrefPubMedGoogle Scholar
• 66 Siegal T, Pfeffer M R, Steiner I. Antibiotic therapy for infected Ommaya reservoir systems.  Neurosurgery. 1988;  22(1 Pt 1) 97-100
  CrossrefPubMedGoogle Scholar
• 67 Kerr J Z, Berg S, Blaney S M. Intrathecal chemotherapy.  Crit Rev Oncol Hematol. 2001;  37(3) 227-236
  CrossrefPubMedGoogle Scholar
• 68 Stapleton S, Blaney S M. New agents for intrathecal administration.  Cancer Invest. 2006;  24(5) 528-534
  CrossrefPubMedGoogle Scholar
• 69 Glantz M J, Cole B F, Recht L et al.. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?.  J Clin Oncol. 1998;  16(4) 1561-1567
  PubMedGoogle Scholar
• 70 Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy.  Cancer. 1998;  82(9) 1756-1763
  CrossrefPubMedGoogle Scholar
• 71 Sampson J H, Archer G E, Villavicencio A T et al.. Treatment of neoplastic meningitis with intrathecal temozolomide.  Clin Cancer Res. 1999;  5(5) 1183-1188
  PubMedGoogle Scholar
• 72 Bernardi R J, Bomgaars L, Fox E et al.. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis.  Cancer Chemother Pharmacol. 2008;  62(2) 355-361
  CrossrefPubMedGoogle Scholar
• 73 Herrlinger U, Weller M, Schabet M. New aspects of immunotherapy of leptomeningeal metastasis.  J Neurooncol. 1998;  38(2-3) 233-239
  CrossrefPubMedGoogle Scholar
• 74 Coakham H B, Kemshead J T. Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients.  J Neurooncol. 1998;  38(2-3) 225-232
  CrossrefPubMedGoogle Scholar
• 75 Chamberlain M C, Kormanik P R. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy.  J Neurooncol. 1997;  35(1) 55-64
  CrossrefPubMedGoogle Scholar
• 76 Chamberlain M C, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy.  Arch Neurol. 1998;  55(4) 506-512
  CrossrefPubMedGoogle Scholar
• 77 Chamberlain M C, Johnston S K, Glantz M J. Neoplastic meningitis-related prognostic significance of the Karnofsky performance status.  Arch Neurol. 2009;  66(1) 74-78
  CrossrefPubMedGoogle Scholar
• 78 Chamberlain M C, Johnston S K. Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology.  Cancer. 2009;  115(9) 1941-1946
  CrossrefPubMedGoogle Scholar
• 79 Garcia-Marco J A, Panizo C, Garcia E S et al.. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.  Cancer. 2009;  115(9) 1892-1898
  CrossrefPubMedGoogle Scholar
• 80 Jaeckle K A, Batchelor T, O'Day S J et al.. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.  J Neurooncol. 2002;  57(3) 231-239
  CrossrefPubMedGoogle Scholar

Marc C ChamberlainM.D. 

Department of Neurology and Neurological Surgery, Division of Neuro-Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance

825 Eastlake Avenue E, POB 19023, MS G4940, Seattle, WA 98109-1023

Email: chambemc@u.washington.edu